Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB

Inclusion Criteria: * Informed consent obtained and signed. * Male or female, aged ≥18 years. * Pulmonary TB diagnosed by Xpert MTB/RIF, Xpert MTB/RIF Ultra, Line Probe Assay (LPA), or mycobacterial culture. * Sputum positive for acid fast bacilli (at least 1+ grade on the WHO scale). * Pulmonary TB diagnosed without known INH resistance (by LPA or Xpert MTB/XDR) and without known RIF resistance (by either LPA or Xpert). Note that phenotypic DST for INH resistance will be done on screening cultures (using MGIT). If baseline molecular or phenotypic test results that become available after enrollment detect resistance to INH or RIF, the participant will be a late exclusion from the study. * Newly diagnosed with TB and have a history of being untreated for at least 6 months after cure from a previous episode of TB. * For participants living with HIV, CD4+ cell count ≥200 cells/mm3, obtained within 30 days prior to study entry. Enrollment of participants living with HIV will be limited to no more than 20% of the total study population. * For participants living with HIV, must be currently receiving or planning to initiate ART at or before study week 8. * Laboratory values at study screening: * Alanine aminotransferase (ALT) ≤3x the upper limit of normal (ULN) * Total bilirubin ≤2.5 x ULN * Creatinine ≤2 x ULN * Potassium ≥3.5 mEq/L, ≤5.5 mEq/L * Absolute neutrophil count (ANC) ≥650/mm3 * Hemoglobin ≥7.0g/dL * Platelet count ≥50,000/mm3 * For females of reproductiv…